Andrew Hutchings
Overview
Explore the profile of Andrew Hutchings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maughan R, Macdonald-Dunlop E, Haroon-Rashid L, Sorensen L, Chaddock N, Masters S, et al.
Arthritis Rheumatol
. 2025 Jan;
PMID: 39817309
Objective: Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large-vessel vasculitis (LVV), can result in serious morbidity. Understanding the molecular basis of LVV should aid...
2.
Alderwick H, Hutchings A, Mays N
BMC Public Health
. 2024 Sep;
24(1):2613.
PMID: 39334058
Background: Policymakers across countries promote cross-sector collaboration as a route to improving health and health equity. In England, major health system reforms in 2022 established 42 integrated care systems (ICSs)-area-based...
3.
Alderwick H, Hutchings A, Mays N
BMJ Open
. 2024 Apr;
14(4):e081954.
PMID: 38589267
Objectives: Major reforms to the organisation of the National Health Service (NHS) in England established 42 integrated care systems (ICSs) to plan and coordinate local services. The changes are based...
4.
Moler-Zapata S, Hutchings A, ONeill S, Silverwood R, Grieve R
Value Health
. 2023 Dec;
27(2):267-269.
PMID: 38128777
No abstract available.
5.
Moler-Zapata S, Hutchings A, ONeill S, Silverwood R, Grieve R
Value Health
. 2023 May;
26(8):1164-1174.
PMID: 37164043
Objectives: International health technology assessment (HTA) agencies recommend that real-world data (RWD) are used in some circumstances to add to the evidence base about the effectiveness and cost-effectiveness of health...
6.
Snowdon C, Silver E, Charlton P, Devlin B, Greenwood E, Hutchings A, et al.
Health Expect
. 2023 May;
26(4):1658-1667.
PMID: 37128669
Background: The COVID-19 pandemic brought rapid and major changes to research, and those wishing to carry out Patient and Public Involvement (PPI) activities faced challenges, such as restrictions on movement...
7.
Ponte C, Grayson P, Robson J, Suppiah R, Gribbons K, Judge A, et al.
Ann Rheum Dis
. 2022 Nov;
81(12):1647-1653.
PMID: 36351706
Objective: To develop and validate updated classification criteria for giant cell arteritis (GCA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in...
8.
Grayson P, Ponte C, Suppiah R, Robson J, Gribbons K, Judge A, et al.
Ann Rheum Dis
. 2022 Nov;
81(12):1654-1660.
PMID: 36351705
Objective: To develop and validate new classification criteria for Takayasu arteritis (TAK). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in six...
9.
Ponte C, Grayson P, Robson J, Suppiah R, Gribbons K, Judge A, et al.
Arthritis Rheumatol
. 2022 Nov;
74(12):1881-1889.
PMID: 36350123
Objective: To develop and validate updated classification criteria for giant cell arteritis (GCA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in...
10.
Grayson P, Ponte C, Suppiah R, Robson J, Gribbons K, Judge A, et al.
Arthritis Rheumatol
. 2022 Nov;
74(12):1872-1880.
PMID: 36349501
Objective: To develop and validate new classification criteria for Takayasu arteritis (TAK). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 6...